Expert review of clinical immunology · 2025
The role of JAK signaling in SpA pathogenesis and its inhibition.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Drosos Alexandros A, Venetsanopoulou Aliki I, Voulgari Paraskevi V
Аннотация
INTRODUCTION: Spondyloarthritis (SpA) includes a group of chronic inflammatory disorders affecting the axial skeleton and/or peripheral joints. The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is pivotal in cytokine-mediated signaling, contributing to SpA pathogenesis.
AREAS COVERED: Cytokine inhibitors were the first biological therapies used in SpA. However, not all patients responded to this treatment. In this setting, Janus Kinase inhibitors (JAKi) have emerged as a promising option for SpA treatment. They act on JAK family members regulating many cytokine signaling pathways involved. Clinical trials have shown significant efficacy for the whole spectrum of SpA phenotypes. However, side effects have emerged and questions arise about their safety profile. This review explores the role of JAK-STAT pathway in SpA, focusing on its involvement in cytokine signaling and immune response regulation, its efficacy, and safety of JAKi. Thus, we searched the relevant literature in PubMed and Scopus from January 2016 until January 2025.
EXPERT OPINION: JAKi are useful in the treatment of SpA and are recommended by international authorities in patients suffering from SpA. Despite the promising results, ongoing research is essential to assess the benefit-risk profile of JAKi in SpA.
AREAS COVERED: Cytokine inhibitors were the first biological therapies used in SpA. However, not all patients responded to this treatment. In this setting, Janus Kinase inhibitors (JAKi) have emerged as a promising option for SpA treatment. They act on JAK family members regulating many cytokine signaling pathways involved. Clinical trials have shown significant efficacy for the whole spectrum of SpA phenotypes. However, side effects have emerged and questions arise about their safety profile. This review explores the role of JAK-STAT pathway in SpA, focusing on its involvement in cytokine signaling and immune response regulation, its efficacy, and safety of JAKi. Thus, we searched the relevant literature in PubMed and Scopus from January 2016 until January 2025.
EXPERT OPINION: JAKi are useful in the treatment of SpA and are recommended by international authorities in patients suffering from SpA. Despite the promising results, ongoing research is essential to assess the benefit-risk profile of JAKi in SpA.